Build your biopharma development and manufacturing knowledge base with the latest whitepapers, application notes, posters, and other educational resources from biopharma industry suppliers.

Antibody Affinity Extraction for HCP Analysis

Ken Hoffman, Eric Bishop, Cygnus Technologies, LLC

Antibody affinity extraction (AAE) is a superior alternative to 2D Western blot for demonstrating host cell protein (HCP) antibody coverage and reactivity to those HCPs that persist through the downstream purification process.

Antibody Drug Conjugate Purification Using TOYOPEARL^® PPG-600M Resin

Tosoh Bioscience LLC

In this application note, antibody drug conjugates (ADCs) were separated into groups with low, medium, and high drug-to-antibody ratios (DARs) using TOYOPEARL PPG-600M resin with a three-step gradient.

Same-Time Protein Concentration and Quality with Stunner

Unchained Labs

The combination of ultraviolet–visible spectral analysis and dynamic light scattering allows for quick quantification and assessment of protein quality. Measure highly concentrated samples accurately without dilutions or cleanup and check for aggregation.

Advanced HDX-MS and Native-MS for Improved Biologic Candidate Selection and Development

Jennifer S. Chadwick, PhD, Kirtland Poss, MBA, Shiaw-Lin Wu, PhD; BioAnalytix

Potential for improving identification of successful biologic drugs and de-risking CMC and clinical designs earlier through strategic application of advanced mass spectrometry (MS), specifically by assessing target engagement using hydrogen deuterium exchange (HDX) and native MS analyses to guide biologic development decisions, is discussed.

See What’s Really in Your Formulation

Halo Labs

In this application note, we explore how backgrounded membrane imaging (BMI), a high refractive index contrast technique used by the HORIZON particle analysis system, performs highly sensitive measurements of subvisible protein aggregates in the 2 µm—4 mm size range, enabling 30% higher reproducibility compared to flow imaging.

Pipelines And Patients Drive Finished Dosage Opportunities

CPhI North America

With fewer compounds available, drug developers are using compounds with good therapeutic effects despite bioavailability challenges for patients to dose less frequently and reduce complexity as a major selling point.